Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 486 across all filing types
Latest filing 2023-11-30 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
关于首次公开发行部分限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from a company regarding the listing and circulation of a portion of restricted shares following an initial public offering (IPO). It details the number of shares becoming tradable, the dates of listing, shareholder commitments, and confirmations from the sponsoring securities firm. The document does not contain financial statements or detailed financial performance data but focuses on the share listing event and related compliance. The length is 3636 characters, which is relatively short and consistent with an announcement rather than a full report. This fits the category of a Share Issue/Capital Change announcement, as it concerns the unlocking and listing of restricted shares post-IPO.
2023-11-30 Chinese
关于投资设立海外全资子公司的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the progress of its investment in establishing an overseas wholly-owned subsidiary. It details board resolutions, investment amounts, changes in shareholding structure, and regulatory filings related to the overseas investment. There are no financial statements, earnings data, or detailed financial analysis present. The document is relatively short (1495 characters) and serves as a progress update on capital investment and regulatory approvals. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2023-11-23 Chinese
海通证券股份有限公司关于和元生物技术（上海）股份有限公司首次公开发行部分限售股上市流通的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Haitong Securities regarding the unlocking and circulation of restricted shares from the initial public offering (IPO) of Heyuan Biotechnology (Shanghai) Co., Ltd. It discusses the types of restricted shares, changes in share capital, shareholder commitments, and compliance with regulatory requirements. The document is not an announcement of a report but a substantive verification opinion related to share circulation post-IPO. It does not contain financial statements or earnings data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a general regulatory filing or announcement but a specific audit/verification report related to share issuance and circulation. Therefore, it fits best under Audit Report / Information (AR). The document length is 4065 characters, which is substantive and not a brief announcement. Hence, the classification is AR with high confidence. Q4 2023
2023-11-16 Chinese
关于首次公开发行部分限售股上市流通公告
Regulatory Filings Classification · 95% confidence The document is an official announcement regarding the listing and circulation of restricted shares following the company's initial public offering (IPO). It details the number of shares becoming tradable, the dates, shareholder commitments, and regulatory approvals. The text includes references to regulatory approvals from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and it discusses share lock-up periods and their expiration. The document is not a financial report, earnings release, or management discussion but rather a formal announcement about the unlocking and circulation of restricted shares. It is also relatively short (3,536 characters) and focused on share circulation details. Therefore, it fits best into the category of Regulatory Filings (RNS), as it is a regulatory announcement that does not fit other more specific categories like Share Issue/Capital Change or Transaction in Own Shares, since it concerns the release of restricted shares post-IPO rather than new issuance or buybacks.
2023-11-16 Chinese
股东减持计划时间届满暨权益变动达1%的公告
Major Shareholding Notification Classification · 100% confidence The document is a detailed announcement regarding the completion of a shareholder's stock reduction plan and the resulting changes in shareholding percentages. It includes specific data on share quantities, percentages, dates, and shareholder identities. The content focuses on the disclosure of shareholding changes by a significant shareholder and their related parties, including the implementation results of the share reduction plan. There is no indication of financial statements, audit opinions, earnings data, or management discussions. The document is not a report itself but a regulatory announcement about shareholding changes. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2023-10-27 Chinese
关于召开2023年第三季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2023 third quarter earnings explanation meeting (业绩说明会) for investors. It provides the date, time, location, participation method, and contact information for the meeting. It references the prior disclosure of the 2023 third quarter report but does not contain any actual financial data or detailed financial analysis itself. The document is short (1545 characters) and serves to inform investors about the upcoming earnings call rather than presenting the earnings results. Therefore, it is best classified as an Investor Presentation (IP) since it relates to a detailed presentation for investors focusing on financial results and interaction, rather than the earnings release (ER) or interim report (IR) itself.
2023-10-25 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.